FLT3 and acute myeloid leukemia: Interesting recent next-generation sequencing analysis on AML at relapse after gilteritinib [65], midostaurin [66] and crenolanib [18] revealed the impact of clonal heterogeneity on the development of resistance to selective FLT3 inhibition in AML.